Schrodinger, Inc. SDGR
Schrodinger, Inc. (Nasdaq: SDGR) is an oncology drug developer. Its lead program, SGR-1505, is in Phase 1 for relapsed or refractory B-cell malignancies. Its next catalyst on record is Bunsen: Full commercial version release (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Bunsen — Full commercial version release (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SGR-1505 | relapsed or refractory B-cell malignancies | small molecule | Phase 1 |
| SGR-3515 | advanced solid tumors | small molecule | Phase 1 |
| SDGR-4594 | immunology and inflammation (undisclosed) | small molecule | Pre-clinical |
| SDGR-8139 | immunology and inflammation (undisclosed) | small molecule | Pre-clinical |
Recent results and decisions
- accepted The FDA accepted Takeda's NDA under Priority Review for zasocitinib, a TYK2 inhibitor co-invented by Schrödinger and Nimbus.
In September, Takeda announced the Food and Drug Administration accepted its New Drug Application under Priority Review for zasocitinib (TAK-279), the company's oral tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasis.
Filing - positive Schrödinger received a milestone payment from Structure Therapeutics associated with Structure's Phase 1/2a study of ACCG-2671, an oral amylin candidate.
Schrödinger received a milestone payment from Structure Therapeutics, a company it co-founded, associated with Structure's Phase 1/2a study of ACCG-2671, its oral small molecule amylin candidate for the treatment of obesity and metabolic diseases.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
- Adlai Nortye Group Ltd. ANL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.